134 related articles for article (PubMed ID: 1834180)
1. Substance P-like immunoreactivity and somatostatin-like immunoreactivity in the ventricular fluid of patients with chronic pain syndromes.
Jost S; Reuner C; Geiger J; Mohadjer M; Milios E; Cramer H
Eur Arch Psychiatry Clin Neurosci; 1991; 241(2):109-12. PubMed ID: 1834180
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus.
Cramer H; Schaudt D; Rissler K; Strubel D; Warter JM; Kuntzmann F
J Neurol; 1985; 232(6):346-51. PubMed ID: 2416886
[TBL] [Abstract][Full Text] [Related]
3. Ventricular fluid neuropeptides in Parkinson's disease. I. Levels and distribution of somatostatin-like immunoreactivity.
Jost S; Reuner C; Mohadjer M; Mundinger F; Cramer H
Neuropeptides; 1990 Apr; 15(4):219-25. PubMed ID: 1979661
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid levels of immunoreactive substance P and somatostatin in patients with multiple sclerosis and inflammatory CNS disease.
Rösler N; Reuner C; Geiger J; Rissler K; Cramer H
Peptides; 1990; 11(1):181-3. PubMed ID: 1692993
[TBL] [Abstract][Full Text] [Related]
5. Alterations in cerebrospinal fluid concentrations of somatostatin-like immunoreactivity in chronic pain patients.
Urban BJ; France RD; Bissette G; Spielman FJ; Nemeroff CB
Pain; 1988 May; 33(2):169-172. PubMed ID: 2967947
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin-like immunoreactivity in cerebroventricular fluid of patients with basal midline tumours.
Cramer H; Weigel K; Rissler K; Milos A; Wolf A; Mundinger F
Neurol Res; 1987 Sep; 9(3):205-10. PubMed ID: 2891071
[TBL] [Abstract][Full Text] [Related]
7. Molecular size distribution of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with degenerative brain disease.
Rissler K; Cramer H; Schaudt D; Strubel D; Gattaz WF
Neurosci Res; 1986 Feb; 3(3):213-25. PubMed ID: 2871533
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid (CSF) neuropeptide Y- and somatostatin-like immunoreactivities in man.
Maeda K; Yasuda M; Kaneda H; Maeda S; Yamadori A
Neuropeptides; 1994 Dec; 27(6):323-32. PubMed ID: 7898640
[TBL] [Abstract][Full Text] [Related]
9. Molecular size distribution of somatostatin-like immunoreactivity in the cerebroventricular fluid of neurosurgical patients.
Rissler K; Jost S; Mohadjer M; Mundinger F; Cramer H
Neurosci Res; 1987 Jun; 4(5):343-56. PubMed ID: 3670743
[TBL] [Abstract][Full Text] [Related]
10. Long-term high frequency transcutaneous electrical nerve stimulation (hi-TNS) in chronic pain. Clinical response and effects on CSF-endorphins, monoamine metabolites, substance P-like immunoreactivity (SPLI) and pain measures.
Almay BG; Johansson F; von Knorring L; Sakurada T; Terenius L
J Psychosom Res; 1985; 29(3):247-57. PubMed ID: 2411923
[TBL] [Abstract][Full Text] [Related]
11. Substance P-like immunoreactivity and analgesic effects of vibratory stimulation on patients suffering from chronic pain.
Guieu R; Tardy-Gervet MF; Giraud P
Can J Neurol Sci; 1993 May; 20(2):138-41. PubMed ID: 7687513
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin-like immunoreactivity in cerebrospinal fluid of patients with complex partial epilepsy.
Pitkänen A; Jolkkonen J; Aikiä M; Sirviö J; Sivenius J; Riekkinen PJ
Eur Neurol; 1988; 28(1):1-5. PubMed ID: 3366146
[TBL] [Abstract][Full Text] [Related]
13. Objective evaluation of pain in various spinal diseases: neuropeptide immunoreactivity in the cerebrospinal fluid.
Imasato H; Nagata K; Hashimoto S; Komori H; Inoue A
Spinal Cord; 1997 Nov; 35(11):757-62. PubMed ID: 9392047
[TBL] [Abstract][Full Text] [Related]
14. Immunoreactive substance P and somatostatin in the cerebrospinal fluid of senile parkinsonian patients.
Cramer H; Rissler K; Rösler N; Strubel D; Schaudt D; Kuntzmann F
Eur Neurol; 1989; 29(1):1-5. PubMed ID: 2468498
[TBL] [Abstract][Full Text] [Related]
15. Elevated cerebrospinal fluid substance P-like immunoreactivity in patients with painful osteoarthritis, but not in patients with rhizopatic pain from a herniated lumbar disc.
Lindh C; Liu Z; Lyrenäs S; Ordeberg G; Nyberg F
Scand J Rheumatol; 1997; 26(6):468-72. PubMed ID: 9433409
[TBL] [Abstract][Full Text] [Related]
16. Ventricular somatostatin-like immunoreactivity in patients with basal ganglia disease.
Cramer H; Wolf A; Rissler K; Weigel K; Ostertag C
J Neurol; 1985; 232(4):219-22. PubMed ID: 2864402
[TBL] [Abstract][Full Text] [Related]
17. [Variation of substance P-like immunoreactivity in plasma and cerebrospinal fluid in the course of arthritis induced by Freund adjuvant in rats, a model for the study of chronic pain].
Calvino B; Maillet S; Pradelles P; Besson JM; Couraud JY
C R Acad Sci III; 1991; 312(8):427-32. PubMed ID: 1905187
[TBL] [Abstract][Full Text] [Related]
18. Ventricular fluid neuropeptides in Parkinson's disease. II. Levels of substance P-like immunoreactivity.
Cramer H; Jost S; Reuner C; Milios E; Geiger J; Mundinger F
Neuropeptides; 1991 Feb; 18(2):69-73. PubMed ID: 1708113
[TBL] [Abstract][Full Text] [Related]
19. Reduced cholinesterase activity and somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with dementia of the Alzheimer type.
Soininen HS; Jolkkonen JT; Reinikainen KJ; Halonen TO; Riekkinen PJ
J Neurol Sci; 1984 Feb; 63(2):167-72. PubMed ID: 6142929
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid somatostatin in delirium.
Koponen H; Stenbäck U; Mattila E; Reinikainen K; Soininen H; Riekkinen PJ
Psychol Med; 1989 Aug; 19(3):605-9. PubMed ID: 2572025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
